3/11 在漢神巨蛋聽了北榮江晨恩教授演講新一代口服抗凝血劑 Dabigatran 的分析:
整理如下
1. Direct thrombin (factor IIa) inhibitor
2. 在 CHADS2 or CHA2DS2-VASc Score 大於或等於 2分的af患者, 不管是 Paroxysmal or permanent af, 給予OAC可以降低Stroke機率
3. Bleeding Risk 可用 HAS BLED Score來評估, 大於或等於 3分風險較高
4. The time in therapeutic range (TTR) 在 af 要控制在 65%以上,能減少STOKE
5. Dabagatran: according to Rely Study
110 mg bid use, superior to warfarin in Major bleeding rate, RRR 20%, p=0.003,
Prevention of hemorrhagic stroke, RRR 69%, p<0.001
and Intracranial bleeding, RRR 69%, p<0.001
150 mg bid use, superior to warfarin in the prevention of stroke and systemic embolism, RRR 34%, p<0.001 ,
vascular mortality, RRR 15%, p=0.04
Prevention of hemorrhagic stroke, RRR 74%, p<0.001
and Intracranial bleeding, RRR 69%, p<0.001 |
最新消息 >